Brief: HLS Therapeutics Says Findings Continue To Reinforce Scientific Data And Clinical Use Of Vascepa To Reduce Cardiovascular Risk

HLS Therapeutics

14/11/2023 22:30

Nov 14 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS INC - FINDINGS CONTINUE TO REINFORCE
SCIENTIFIC
DATA AND CLINICAL USE OF VASCEPA® TO REDUCE CARDIOVASCULAR RISK
    * HLS THERAPEUTICS INC - ANALYSIS ALSO FOUND ICOSAPENT ETHYL
WAS
ASSOCIATED WITH A 41% REDUCTION IN TOTAL EVENTS COMPARED WITH
PLACEBO
    * HLS THERAPEUTICS INC - FINDINGS CONTINUE TO REINFORCE
SCIENTIFIC
DATA AND CLINICAL USE OF VASCEPA(® )TO REDUCE CARDIOVASCULAR
RISK
    * HLS THERAPEUTICS INC - HAS IN-LICENSED EXCLUSIVE RIGHTS TO
VASCEPA FOR CANADIAN MARKET FROM AMARIN CORPORATION PLC

Source text for Eikon:  ID:nCNW5pV7na 
Further company coverage:  HLS.TO 

 ((reuters.briefs@thomsonreuters.com;))